Altimmune (ALT) Earnings Call Presentation

Efficacy Highlights - Pemvidutide demonstrated statistically significant MASH resolution without worsening of fibrosis, reaching up to 59.1% at 24 weeks[55] - Fibrosis improvement without worsening of MASH was observed in up to 34.5% of patients at 24 weeks[55] - Liver fat content was reduced by up to 62.8%[55] - Patients experienced weight loss of up to 6.2% which continued through 24 weeks without plateauing[55] Safety and Tolerability - The trial showed potentially best-in-class tolerability with a low discontinuation rate of less than 1% due to adverse events in subjects receiving pemvidutide[55] - There were no heart rate increases or differences in cardiac adverse events between the pemvidutide and placebo groups[55] Additional Benefits - Pemvidutide maintained HbA1c levels regardless of diabetes status[55] - The trial observed statistically significant improvements in non-invasive tests of fibrosis[55] - Alanine Aminotransferase (ALT) was significantly reduced in ITT Analysis, with reductions of -34.4 IU/L in the 1.2 mg group and -34.6 IU/L in the 1.8 mg group compared to -10.0 IU/L in the placebo group[40]